| Literature DB >> 26413329 |
Khaled Mohyelden1, Osman Abdel-Kader2.
Abstract
OBJECTIVES: To evaluate a new technique, the rectal balloon (RB), to control blood loss after transvesical prostatectomy (TVP). PATIENTS AND METHODS: Over 2 years 100 patients were prospectively randomised into two equal groups. All patients underwent TVP for their benign prostatic hyperplasia but a RB (a balloon fixed to a three-way Foley catheter tip by a plaster strip, making it airtight) was used in group 2. The RB was placed in the rectum opposing the prostate and inflated (pressure controlled) for 15 min. Haemoglobin levels were assessed before and after TVP. Blood transfusion, the amount of saline used for irrigation, duration of catheterisation, hospital stay, and rectal complaints were recorded. Patients were followed up at 1 and 3 months after TVP.Entities:
Keywords: BPH; Open prostatectomy; PVR, postvoid residual urine volume; Qmax, maximum urinary flow rate; RB, rectal balloon; Rectal balloon; Surgical management; TVP, transvesical prostatectomy; Transvesical
Year: 2015 PMID: 26413329 PMCID: PMC4561921 DOI: 10.1016/j.aju.2014.12.003
Source DB: PubMed Journal: Arab J Urol ISSN: 2090-598X
Figure 1The composition of the RB. (A) Two balloons, the three-way Foley catheter and the sphygmomanometer. (B) The RB assembled.
Figure 2A diagram showing the position of RB.
Figure 3(A) The RB assembled ready for use. (B) A patient undergoing TVP with the RB in situ. (C) An enucleated adenoma (78 g). (D) A radiograph showing the balloon in the rectum (with contrast medium between the two balloons of the RB, and in the balloon of the urethral catheter).
The baseline characteristics, changes in haemoglobin, operative values, and the efficacy of TVP in the two groups.
| Mean (SD, range) | Group 1 | Group 2 | ||
|---|---|---|---|---|
| Age (years) | 65.6 (4.1, 58–74) | 66.5 (4.5, 57–75) | 0.34 | |
| IPSS | 24 (3.6, 20–32) | 23.5 (3.7, 20–31) | 0.49 | |
| Urinary flow rate, mL/s | ||||
| Mean | 3.7 (2.1, 0–6) | 3.6 (1.9, 0–6.2) | 0.59 | |
| | 6.8 (3.8, 0–10.9) | 6.6 (3.3, 0–11) | 0.90 | |
| Haemoglobin (g/dL) | 13.6 (1.1, 11.4–15.4) | 12.9 (0.9, 11.8–14.6) | 0.45 | |
| Prostate volume (mL) | 121.8 (43.3, 81–270) | 125.1 (48.6, 82–255) | 0.73 | |
| PVR (mL) | 214 (217, 75–780) | 195 (210, 70–750) | 0.69 | |
| Changes in haemoglobin level (g/dL) | ||||
| Loss during TVP | 0.83 (0.37, 0.5–1.9) | 0.72 (0.29, 0.5–1.8) | 0.42 | |
| Loss within 1st 24 h | 0.94 (0.31, 0.5–1.4) | 0.23 (0.12, 0.1–0.5) | 0.008 | |
| Loss to 1 day after TVP | 1.77 (0.56, 1–3.2) | 0.95 (0.38, 0.6–2.3) | 0.001 | |
| Total loss (3 days) | 1.96 (0.41, 1.3–3.3) | 1 (0.32, 0.8–2.4) | 0.003 | |
| Saline (L) | 11.5 (2.8, 7–18) | 2.5 (0.5, 1.7–3.5) | 0.009 | |
| Catheter duration (days) | 5.7 (0.7, 5–9) | 4.3 (0.4, 4–5.5) | 0.002 | |
| Hospital stay (days) | 6.2 (1, 5.5–10) | 5.1 (0.4, 4.5–6) | 0.003 | |
| Efficacy of TVP | ||||
| PVR (mL) | Before | 214 (217) | 195 (210) | 0.001 |
| After | 8 (4) | 10 (3) | ||
| IPSS | Before | 24 (3.6) | 23.5 (3.7) | 0.003 |
| After | 2 (1) | 2 (1) | ||
| | Before | 6.8 (3.8) | 6.6 (3.3) | 0.001 |
| After | 26 (3) | 25 (3) | ||
By TRUS.